Clinical Trial Update: HAIC in Combination with PD-1 Inhibitors and Lenvatinib for Intermediate and Advanced HCC After the Failure of Systemic Therapy Recommended by BCLC

View source ↗

Summary

A registered clinical trial is evaluating hepatic arterial infusion chemotherapy in combination with PD-1 inhibitors and lenvatinib for intermediate and advance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Hepatic Arterial Infusion Chemotherapy
• Lenvatinib (lenvatinib)

Snippet

Sponsor: First Hospital of China Medical University | Conditions: BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma | Status: RECRUITING